News on Biospecifics Technologies Corporation from BioPortfolio.com http://www.BioPortfolio.com Consolidated Biospecifics Technologies Corporation news from BioPortfolio.com Wed, 10 Feb 2010 11:49:58 GMT en Judge schedules next phase of LightLab Imaging's damages trial against Volcano and Axsun Technologieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041204&HITNO=0&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041204&THISHREF=http://c.moreover.com/click/here.pl%3fz2539033533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041204&HITNO=0&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041204&THISHREF=http://c.moreover.com/click/here.pl%3fz2539033533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAVhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040175&HITNO=1&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040175&THISHREF=http://c.moreover.com/click/here.pl%3fz2538629444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040175&HITNO=1&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040175&THISHREF=http://c.moreover.com/click/here.pl%3fz2538629444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatmenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039878&HITNO=2&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039878&THISHREF=http://c.moreover.com/click/here.pl%3fz2538446120%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039878&HITNO=2&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039878&THISHREF=http://c.moreover.com/click/here.pl%3fz2538446120%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly feverhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039451&HITNO=3&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039451&THISHREF=http://c.moreover.com/click/here.pl%3fz2538122681%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039451&HITNO=3&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039451&THISHREF=http://c.moreover.com/click/here.pl%3fz2538122681%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: SAIC Completes Acquisition of Cybersecurity Solutions Provider CloudShield Technologies, Inc.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038105&HITNO=4&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038105&THISHREF=http://c.moreover.com/click/here.pl%3fz2537473492%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038105&HITNO=4&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038105&THISHREF=http://c.moreover.com/click/here.pl%3fz2537473492%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: 192 (Last)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038437&HITNO=5&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038437&THISHREF=http://c.moreover.com/click/here.pl%3fz2537609163%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038437&HITNO=5&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038437&THISHREF=http://c.moreover.com/click/here.pl%3fz2537609163%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioresearch Online: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Global Med Technologies, Inc.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036952&HITNO=6&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036952&THISHREF=http://c.moreover.com/click/here.pl%3fz2536838869%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036952&HITNO=6&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036952&THISHREF=http://c.moreover.com/click/here.pl%3fz2536838869%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Medical News: Dynavax Initiates Large-Scale Phase 3 Trial Of HEPLISAVTMhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036818&HITNO=7&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036818&THISHREF=http://c.moreover.com/click/here.pl%3fz2536769775%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036818&HITNO=7&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036818&THISHREF=http://c.moreover.com/click/here.pl%3fz2536769775%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Dynavax Initiates Large-Scale Phase 3 Trial Of HEPLISAVTMhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036267&HITNO=8&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036267&THISHREF=http://c.moreover.com/click/here.pl%3fz2536544045%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036267&HITNO=8&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036267&THISHREF=http://c.moreover.com/click/here.pl%3fz2536544045%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Ozmo Devices Announces New CEO Bill McLean to Take Reins of Wi-Fi PAN Market Leaderhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035408&HITNO=9&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035408&THISHREF=http://c.moreover.com/click/here.pl%3fz2536229282%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035408&HITNO=9&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035408&THISHREF=http://c.moreover.com/click/here.pl%3fz2536229282%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: NIH awards over $15M for Tulane University's collaborative effort to combat VHFhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033977&HITNO=10&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033977&THISHREF=http://c.moreover.com/click/here.pl%3fz2535526139%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033977&HITNO=10&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033977&THISHREF=http://c.moreover.com/click/here.pl%3fz2535526139%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: NIH awards over $15M for Tulane University's collaborative effort to combat VHFhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033976&HITNO=11&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033976&THISHREF=http://c.moreover.com/click/here.pl%3fz2535525814%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033976&HITNO=11&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033976&THISHREF=http://c.moreover.com/click/here.pl%3fz2535525814%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Dechttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033813&HITNO=12&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033813&THISHREF=http://c.moreover.com/click/here.pl%3fz2535410854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033813&HITNO=12&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033813&THISHREF=http://c.moreover.com/click/here.pl%3fz2535410854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioscience Technology Online: Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033653&HITNO=13&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033653&THISHREF=http://c.moreover.com/click/here.pl%3fz2535307824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033653&HITNO=13&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033653&THISHREF=http://c.moreover.com/click/here.pl%3fz2535307824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsBlaze: Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033449&HITNO=14&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033449&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033449&HITNO=14&MSIZE=445&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Biospecifics%20Technologies%20Corporation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033449&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: